Tag:
Acetylon Pharmaceuticals
Latest Headlines
Latest Headlines
4SC surges on positive midstage data for advanced liver cancer
Shares of Germany's 4SC ( $VSC ) surged 35% after investigators reported promising mid-stage data for the cancer drug resminostat, an HDAC inhibitor, in difficult-to-treat patients with advanced liver
Acetylon grabs $27M in venture cash for next-gen HDAC inhibitor
A little less than two years since it closed its Series A round, Boston-based Acetylon Pharmaceuticals has gone back to its investors for $27 million to fund continued work on a next-gen HDAC
Acetylon raises $12.4M in new venture round
Boston upstart Acetylon Pharmaceuticals has raised $12.4 million in new venture funds, according to MassHighTech. Citing SEC documents the news service revealed that Acetylon is in the process of
Cambridge startup launches HDAC platform with Series A
Cambridge, MA-based startup Acetylon Pharmaceuticals is taking the wraps off a $7.25 million Series A later today as it sets out to zero in on a lead program and demonstrate the effectiveness of a
